#USA #Fort Lauderdale #Wound Care #MolecuLight #CAMPS 2025

MolecuLight's Groundbreaking Presentation at CAMPS 2025

MolecuLight Inc., a frontrunner in the development of point-of-care fluorescent imaging devices, has announced its participation in the much-anticipated CAMPS (Cellular, Acellular, and Matrix-like Products) meeting slated to occur from February 28 to March 2, 2025, in Fort Lauderdale, Florida. Their presence at booth number 21 and their podium discussions will provide attendees an opportunity to discover how their cutting-edge technology can revolutionize wound assessment and treatment decisions, especially in light of the new proposals regarding Local Coverage Determination (LCD) language for skin substitutes.

One of the most notable innovations by MolecuLight is the ability to utilize fluorescence imaging to instantly visualize harmful bacterial load in infected wounds. This real-time information equips healthcare professionals to treat patients more effectively, often leading to faster healing times and improved outcomes. The MolecuLight devices guide specific therapies and optimize wound treatment strategies based on immediate, actionable insights.

Anil Amlani, CEO of MolecuLight, articulated the significance of this technology, stating, “Our innovations address a critical need in wound care by granting healthcare providers visibility into what was previously unseen. By visualizing bacterial presence, we can substantiate the efficacy of advanced therapies like CAMPs, improve patient outcomes, and ultimately reduce the burden of chronic wounds.”

The new LCD language proposal for skin substitutes emphasizes the necessity for exhaustive evaluation and documentation of wounds. In line with this, MolecuLight's comprehensive imaging and measurement devices support these standards by providing:

• - Objective visual evidence of wound status
• - Automated and precise wound measurements
• - Enhanced documentation to justify the medical necessity for advanced therapies.

Amlani further noted, “MolecuLight's capacity to deliver real-time objective data aligns seamlessly with the evolving standards for documentation and treatment in wound care. We’re excited to demonstrate how our technology can help healthcare providers meet the requirements stated in the proposed LCD language while delivering optimal patient care.”

Visit MolecuLight at CAMPS 2025

Participants at the CAMPS 2025 meeting are warmly encouraged to visit MolecuLight at booth #21 to experience their technology first-hand and to learn about its applications, not only concerning CAMPs but also across the entire spectrum of wound care. Additionally, attendees are invited to partake in the session titled "Ensuring Optimal Outcomes with CAMP," scheduled for February 28 from 11:25 AM to 12:45 PM, where MolecuLight will elaborate on how innovative technology can enhance bed preparation and optimize CAMP outcomes.

About MolecuLight

MolecuLight Inc. is a private global medical imaging company dedicated to creating and marketing the MolecuLight iX® and DX™ imaging devices. These are the only Class II point-of-care imaging devices approved by the FDA, designed specifically for real-time detection of elevated bacterial loads in wounds. They also offer precise digital wound measurements that support comprehensive treatment, underpinned by robust clinical evidence, including over 100 peer-reviewed publications. For sales inquiries, media requests, or additional information, please contact:

Hunter Zudans
Director of Marketing
MolecuLight Inc.
Phone: +1.484.682.7580
Email: [email protected]
Website: www.moleculight.com



This coverage aims to shed light on the latest advancements in wound care technology, demonstrating a significant step forward in how healthcare providers can manage challenging cases of chronic wounds and enhance patient care.